With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Exceeding the target of 1.50 lakh Ayushman Bharat - Health & Wellness Centres (AB-HWC) by 31 December, 2022, more than 1.54 lakh Sub Health Centres and Primary Health Centres have been transformed as AB-HWCs
The company has played an important role in the procurement and distribution of emergency medical supplies supporting the Union Health Ministry for Covid–19 pandemic management
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Subscribe To Our Newsletter & Stay Updated
